Pages Menu
FacebookTwitterPinterestRss
Categories Menu

Posted by on Mar 4, 2016 in Foundation NewsLine, Type C |

Vtesse Inc. Announces Phase 1/2 Clinical Data Showing Slowing of Disease Pregression from VTS-270 Treatment for Niemann-Pick Type C1 Disease

vtesse_000_001_001The National Niemann-Pick Disease Foundation (NNPDF) is pleased to share with our NPC Community Members a press release from Vtesse, Inc. regarding data from the Phase 1/2 clinical trial that was presented at the 2016 World Symposium on Lysosomal Storage Disease in San Diego, California.

GAITHERSBURG, Md., March 4, 2016 /PRNewswire/ — Vtesse, Inc. announced today data from a Phase 1/2 clinical trial demonstrating a reduction in the rate of Niemann-Pick Type C1 (NPC1) Disease progression from Vtesse’s lead drug candidate VTS-270. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Center for Advancing Translational Sciences, two components of the National Institutes of Health, collaborated closely with patients, patient advocacy groups and academia to initiate the drug development phase for VTS-270. Vtesse is leading the late-stage formal drug development process.

The data were presented at the 2016 World Symposium on Lysosomal Storage Disease in San Diego, California.

Click here to read the full Press Release dated 4 March 2016.